Merck’s Livingston facility has received £2.6 million in funding to support the launch of a product used in analysing blood

Merck’s Livingston facility has benefited from a £2.6 million investment to support the launch of a product used in analysing blood.

Scottish Enterprise provided a research and development grant to underpin the design and development of the diagnostic quality control kit which has received regulatory approval around the world and has helped secure the status of the West Lothian plant.

Full product launch is expected from next month which will also see the creation of 15 jobs.

Site director, Adrian Birkett said; “The investment is a just recognition of the incredible work being done by the team here in Livingston.

“We aim to impact life and health with science by driving scientific breakthroughs and accelerating innovation. Science and technology are advancing at an unprecedented speed, and with that are the needs and expectations of our customers worldwide.

“Project funding through the award of a grant from Scottish Enterprise was crucial in securing the project in Scotland and has allowed the permanent recruitment of R&D, engineering, project management and validation jobs at the site.”

Read the full article on "Daily Business" here.